Esperion Therapeutics, Inc. (ESPR) on Tuesday said it has agreed to acquire Corstasis Therapeutics Inc. for $75 million in upfront cash, with up to an additional $180 million tied to regulatory and commercial milestones, plus low double-digit royalties on sales of Enbumyst and related follow-on products. The company's shares were down more than 11% in pre-market trading.
The acquisition adds Enbumyst, the first and only nasal spray diuretic approved by the U.S. Food and Drug Administration for edema associated with congestive heart failure and hepatic and renal disease in adults, to Esperion's portfolio. It also brings Corstasis' subcutaneous pipeline in development, including a multidose pen injector with the potential to unlock additional market opportunities.
The transaction is expected to close in the second quarter of 2026.
"We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders - from patients and providers to employees and shareholders," stated Sheldon Koenig, President and Chief Executive Officer of Esperion.
Esperion shares closed at $3.27 on Monday, down 2.39%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.